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Abstract 1 
    The skin disposition of topically applied lidocaine hydrochloride was determined 2 
under steady-state skin permeation by imaging mass spectrometry (MSI).  The 3 
distribution of lidocaine in pig ear skin was assessed using MALDI-TOF-MS with mass 4 
images being examined with BioMap software.  Following the detection of intrinsic 5 
signals of lidocaine, the skin concentration-distance curve was obtained using 6 
brightness analysis ([M+H+]: m/z 235.18).  Although the skin concentration profile 7 
obtained by MALDI-TOF-MS did not completely correspond to the calculated one 8 
obtained from the skin permeation profile, the skin concentration profile could be 9 
detected.  These results demonstrate that imaging MSI might be a useful method that 10 
can be used to determine the skin disposition of topically applied non-radiolabeled or 11 
non-fluorescent drugs. 12 
 13 
Keywords: imaging mass spectrometry; transdermal delivery; topical application; skin 14 
concentration; skin distribution  15 
 16 
 17 
  18 
 3 
1. Introduction 1 
    The skin disposition of topically applied drugs is known to be strongly associated 2 
with local efficacy and toxicity (Holford et al., 1981).  Dermatopharmacokinetics 3 
(Alberti et al., 2001) (DPK) is now being utilized to evaluate generic topical 4 
formulations in Japan (www.nihs.go.jp/drug/be-guide(e)/Topical_BE-E.pdf).  The skin 5 
concentrations of topically applied drugs have previously been assessed using several 6 
methods, including tape stripping (Pershing et al., 1992; N'Dri-Stempfer et al., 2009), 7 
heat separation (Surber et al., 1990), and others (Kiistala, 1968; Surber et al., 1993), 8 
which generally require drug extraction and tissue homogenization procedures.  9 
However, difficulties have been reported in accurately determining the drug distribution 10 
or drug concentration-distance profiles in the skin by these methods.  The skin 11 
permeation profiles of topically applied drugs can be analyzed by Fick’s second law of 12 
diffusion under the assumption that the skin consists of one or two homogeneous 13 
membranes (Sugibayashi et al., 2010).  We recently reported that the skin 14 
concentrations of topically applied drugs in a certain logarithmic range of the 15 
n-octanol/water coefficient, logKo/w (1.93 < logKo/w < 2.81), could be calculated with a 16 
two-layered diffusion model, with a relationship being identified between the calculated 17 
and observed steady-state concentrations of drugs.  On the other hand, the skin 18 
concentrations of hydrophilic drugs (logKo/w ≤ 0) could not be accurately determined 19 
using the same method.  Several studies (Lademann et al., 1999; Toll et al., 2004; 20 
Trauer et al., 2009; Marshall et al., 2010) confirmed that hair follicles and sweat ducts 21 
were the primary permeation pathways for hydrophilic drugs and macromolecules.  22 
 4 
Fluorescence dyes such as calcein, fluorescein, and fluorescein isothiocyanate dextran 1 
(FITC-dextran) have been used as model hydrophilic drugs and macromolecules in 2 
order to provide insight into their skin disposition following topical application.  3 
However, this technique can only be used for fluorescent compounds.   4 
  Recently, several studies have used mass spectrometry imaging (MSI) by 5 
matrix-assisted laser desorption/ionization (MALDI) to investigate the disposition of a 6 
drug after its topical application (Marshall et al., 2010; Enthaler et al., 2011).  In 7 
addition, D’Alvise et al. have reported that the follicular transport of lidocaine in the 8 
deeper skin layers and its metabolism in subcutaneous tissue could be detected by 9 
desorption electrospray ionization mass spectrometry imaging (D’Alvise et al., 2014).    10 
  The observation of heterogeneous drug distribution in skin, such as localized drug 11 
distributions in hair follicles, using a horizontal or vertical skin section with a 12 
microscope would provide us with very useful information to reveal the skin permeation 13 
route of topically applied drugs.  Since the pharmacological and toxicological effects 14 
of topically applied chemicals can be determined by their concentration at the viable 15 
epidermis/dermis, drug concentration-depth profile in viable epidermis/dermis should 16 
be investigated in order to evaluate the safety and effects.  Bunch et al. have reported 17 
that a quantitative skin profile of ketoconazole was acquired with MALDI quadrupole 18 
time-of-flight mass spectrometry (Q-TOFMS) (Bunch et al., 2004).  However, no 19 
comparison of skin concentration profiles obtained by imaging MALDI-TOF MS and a 20 
conventional method has been performed to investigate the usefulness of the novel 21 
method.   22 
 5 
  In the present study, an atmospheric-pressure MALDI quadrupole-ion-trap TOF-MS 1 
(AP-MALDI-QIT-TOF-MS) instrument was first used with 10-µm spatial resolution to 2 
obtain positional information on the concentration of a drug in skin following its topical 3 
application.  Lidocaine hydrochloride was used as a model drug to observe the drug 4 
concentration-distance profile by MALDI-TOFS because its skin permeation profile 5 
could be successfully calculated with Fick’s second law of diffusion from the skin 6 
permeation profile.    7 
 8 
2. Experimental 9 
2.1. Materials and methods 10 
    Lidocaine hydrochloride was obtained as a model drug from Sigma Aldrich (St. 11 
Louis, MO, U.S.A.). Other reagents and solvents were of reagent or HPLC grade and 12 
used without further purification.  Frozen pig ear skin (three-breed cross pigs involving 13 
the Landrace, Yorkshire and Durocbreeds) was purchased from the National Federation 14 
of Agricultural Cooperative Associations (Tokyo, Japan).  The skin samples were 15 
stored at -30°C until the skin permeation experiments.   16 
 17 
2.2. Preparation of skin membrane 18 
  The purchased skin was maintained frozen at -80°C prior to use.  The skin was 19 
thawed at 32°C and excised from the outer surface of a pig ear after being cleaned with 20 
distilled water.  Stripped skin was obtained by tape stripping of the stratum corneum 21 
 6 
(SC) with adhesive tape (Scotch®; 3M Japan Ltd., Tokyo, Japan) 20 times prior to its 1 
excision from the pig ear.  Excess fat was carefully trimmed off from the excised skin 2 
with a knife.	   3 
 4 
2.3. Skin permeation experiments for lidocaine 5 
  The skin sample was set in a vertical-type diffusion cell (effective diffusion area: 1.77 6 
cm2) in which the skin surface temperature was maintained at 32°C.  After 1 h of 7 
hydration with phosphate-buffered solution (PB), PB containing 2.5 mg/mL lidocaine 8 
(volume: 1.0 mL) was applied to the SC side as a donor solution for 8 h, and PS 9 
(volume: 6.0 mL) was added to the dermis side as a receiver solution. The receiver 10 
solution was stirred with a stirrer bar on a magnetic stirrer. An aliquot (500 µL) was 11 
withdrawn from the receiver chamber and the same volume of PB was added to the 12 
chamber to keep the volume constant.  The penetrant concentration in the receiver 13 
chamber was determined by HPLC.  Three skin permeation experiments were 14 
conducted to calculate the skin concentration-distance profile. 15 
 16 
2.4. HPLC conditions 17 
Ethyl paraben (EB) was used as an internal standard (IS) in the quantitative 18 
determination of lidocaine.  An aliquot of a sample solution containing lidocaine was 19 
mixed with acetonitrile (1:1) and centrifuged (15,000 × rpm, 5 min, 4ºC) to obtain 20 
supernatant.  Then, 20 µL of obtained supernatant was injected into the HPLC system.  21 
The HPLC system consists of a pump (LC-20AD), a UV detector (PD-20A), a 22 
 7 
system controller (SCL-10AVP), an auto-injector (SIL-20A), a degasser 1 
(DGU-20A3), a column oven (CTO-20A), and analysis software (LC solution) 2 
(all from Shimadzu, Kyoto, Japan).  An Inertsil→ ODS-3 5 µm, 4.6×150 mm 3 
(GL Sciences Inc., Tokyo, Japan) column was kept at 40°C.  The mobile 4 
phase was 0.1% phosphoric acid:acetonitrile = 7:3, containing 5.0 mM 5 
1-heptanesulfonate at a flow rate of 1.0 ml/mL.  Detection was carried out 6 
at UV 230 nm. 7 
 8 
2.5. Preparation of skin samples to plot lidocaine calibration curve 9 
 The stripped skin was immersed in different concentrations of lidocaine solution (500, 10 
1500, and 2500 µg/mL) for 24 h to obtain skin with homogeneously distributed 11 
lidocaine.  A calibration curve for the skin concentration of lidocaine was obtained by 12 
imaging analysis of the treated skin.    13 
 14 
2.6. Skin treatment for MALDI-TOFS observation 15 
    After the permeation experiment or after immersion in lidocaine solutions to obtain 16 
a calibration curve, the skin surface was washed three times using 1 mL of ultrapure 17 
water.  The skin was then embedded in 2.0% carboxymethyl cellulose and frozen in 18 
isopentane at -80°C.  The embedded skin was sliced using a cryostat (CM3050; Leica 19 
Microsystems, Wetzler, Germany) to obtain 7-µm-thick vertical sections at -20°C.  20 
Then, each skin section was kept at room temperature for 30 min before subjecting it to 21 
MALDI-QIT-TOF-MS.  These sections were mounted on an indium tin oxide-coated 22 
 8 
slide glass (Sigma-Aldrich), dried in a silica gel-containing plastic tube, and then 1 
sprayed with 2,5-dihydroxybenzoic acid (DHB; 50 mg/mL in 70% methanol and 30% 2 
water containing trifluoroacetic acid at a concentration of 0.1%) using a 0.2-mm-nozzle 3 
caliber airbrush (Procon Boy FWA Platinum; Mr. Hobby, Tokyo, Japan) to conduct 4 
MALDI-imaging mass spectrometry in the positive-ion mode.  MALDI-QIT-TOF-MS 5 
equipped with a 355-nm Nd:YAG laser and microscope allowed mass images to be 6 
obtained with a high spatial resolution of 10 µm, in the scan range of m/z 200-900, as 7 
described previously for a prototype MALDI-imaging mass spectrometry instrument 8 
(Marshall et al., 2010) (Mass Microscope; Shimadzu, Kyoto, Japan).  Microscopic 9 
images were obtained after application of a matrix (300 µL of DHB solution) to the skin 10 
sections.  Mass spectra were subsequently acquired in the positive-ion mode in the 11 
designated areas of a specimen.   12 
 13 
2.7. Image analysis of skin sections using BioMap®  14 
    The distribution of the specific signal intensity of lidocaine ([M+H+]: m/z 235.18) 15 
in the skin was assessed using AP-MALDI-TOF-MS with mass images being examined 16 
with BioMap® software (Novartis Pharma K.K., Basel, Switzerland). The brightness of 17 
the obtained skin section images was analyzed using the image processing software 18 
Image J® (National Institutes of Health, Bethesda, MD, U.S.A.). Figure 1a shows 19 
microscopic observation results of a skin section.  The measurement area in the skin 20 
section was decided by the positional information of the obtained image and the area, 21 
and was then divided into 5 sections (the size of each section: 260 µm long Í 500 µm 22 
 9 
wide) from the surface of stratum corneum side (x = 0) to calculate the brightness 1 
intensity (Figure 3b).  The average brightness value in each section was obtained using 2 
Image J software (ver. 1.48).  In the case of the full-thickness skin to measure the skin 3 
concentration of lidocaine, the outermost section to the stratum corneum side was 4 
further divided into two sections; the size of the outermost section was 20 µm long Í 5 
500 µm wide and that of the other one was 240 µm long Í 500 µm wide.   6 
 7 
2.8. Calculation of skin concentration from skin permeation profile 8 
  The calculated skin concentration of lidocaine was obtained by curve-fitting the 9 
cumulative amount of it that permeated through the full-thickness skin and stripped skin 10 
to the theoretical values, where the theoretical values could be expressed by Fick’s 11 
second law of diffusion in the stratum corneum and viable epidermis and dermis.  12 
Differential equations describing Fick’s second law are as follows.  13 
     
   
!"#,%&'!( = *∆( (𝐶.,/0* − 𝐶.,/)                                      (1) 14 
     
   
!"#,%!34 = *∆34 (𝐶.5*,/ − 2𝐶.,/ + 𝐶.0*,/)                               (2) 15 
The mathematical approach for determining skin permeation using a two-layered 16 
diffusion model was the same as in our previous method (Sugibayashi et al., 2010).  17 
Skin permeation parameters such as permeability coefficient, diffusion coefficient, and 18 
partition coefficient were obtained by curve-fitting to the obtained permeation profiles 19 
with a two-layered diffusion model. 20 
 21 
 10 
 1 
2.9.  Measurement of skin thickness 2 
 The thicknesses of the stratum corneum, epidermis, and whole skin in pig ear skin was 3 
microscopically determined from microtomed sections after hematoxylin–eosin staining. 4 
Five section selected at random from each specimen were used to measure the stratum 5 
corneum, and whole skin thicknesses were measured by a light micrograph (IX71; 6 
Olympus Corp., Tokyo, Japan) and a calibrated ocular micrometer. The thickness of the 7 
epidermis was calculated by subtracting the stratum corneum thickness from the whole 8 
skin thickness. 9 
 10 
3. Results 11 
3.1. Skin permeation profile of lidocaine 12 
 Figure 1 shows the skin permeation profiles of lidocaine through full-thickness skin 13 
and stripped skin after its topical application.  The cumulative amount of lidocaine that 14 
permeated through the stripped skin was much higher than that through the 15 
full-thickness skin.  Skin permeation parameters obtained from the permeation profiles 16 
through the full-thickness and stripped skin are listed in Table 1.  Since the skin 17 
thickness of stratum corneum and viable epidermis and dermis were 19.0 ± 2.0 µm 18 
(mean ± S.E.) and 1406 ± 38 µm (mean ± S.E.), these values were set to calculate the 19 
skin permeation parameters.  The skin concentration-distance profiles in full-thickness 20 
and stripped skin that were calculated with the skin permeation parameters are shown in 21 
Figures 6a and b, respectively.  The ratio of lidocaine concentration at depth 0 to the 22 
 11 
distance from the stratum corneum was much higher than that at other distance points, 1 
and the lidocaine concentration in the skin gradually decreased toward the dermis side 2 
from the stratum corneum.  3 
 4 
Fig. 1 5 
 6 
3.2. Fractionation of lidocaine signals by MSI 7 
Figure 2 shows a typical mass spectrum, collected from m/z=200 to 900, of a skin 8 
section after the topical application of lidocaine.  The mass peak of protonated 9 
lidocaine was present (m/z 235.18) in the skin section.  10 
 11 
Fig. 2 12 
 13 
3.3. MSI observations of pig ear skin sections and image analysis using BioMap® 14 
    Figure 3a shows optical images of a skin section after the skin had been immersed 15 
in lidocaine solution at a concentration of 1500 µg/mL in order to obtain a calibration 16 
curve.  The distribution of lidocaine was determined in a designated square area of the 17 
skin that is enclosed by black lines in Fig. 3a.  Figure 3b shows the distribution of 18 
lidocaine, which could be identified by MS analysis and visualized as mass images with 19 
BioMap software. The skin distribution of lidocaine is shown as a red spot. The 20 
[M+H+] signal was detected in the whole area of the skin.   21 
 22 
 12 
Figs. 3a and 3b 1 
 2 
3.4. Imaging analysis of lidocaine in skin sections using Image J software 3 
    To evaluate the skin distribution of lidocaine, the distribution of signals was 4 
quantified based on the depth direction using Image J software. Figures 4a and b show 5 
optical images of a skin section and the lidocaine distribution in the stripped skin after 6 
immersion in solutions with different concentrations of lidocaine (0, 500, 1500, and 7 
2500 µg/mL), respectively.  Lidocaine distributions were observed in each skin sample, 8 
and the brightness of red spots increased with an increase of the applied concentration 9 
of lidocaine.  Figure 4c shows the correlation between brightness intensity and skin 10 
concentration of lidocaine.  A good relationship (R2=0.998) was observed within the 11 
range of lidocaine concentrations up to 2500 µg/mL.   12 
 13 
Figures 4a, 4b, and 4c 14 
 15 
 Figures 5 and 6 show lidocaine distribution and its concentration-depth profiles in the 16 
stripped skin and the viable epidermis and dermis parts of full-thickness skin.  The 17 
lidocaine distributions were detected in both stripped skin and full-thickness skin and 18 
many bright dots were confirmed in stripped skin compared with those in full-thickness 19 
skin.  The obtained skin concentrations from MSI analysis were corrected with Kved 20 
value of lidocaine and the observed skin concentrations was plotted against the average 21 
value of the depth of each skin section.  As shown in Fig. 6, calculated lidocaine 22 
 13 
concentration in skin was decreased in the stripped skin as well as in the full-thickness 1 
skin toward the dermis from the stratum corneum side.  The observed lidocaine 2 
concentration in stripped skin was lower than calculated one, whereas the observed 3 
concentration in full-thickness skin was higher than calculated one.  Although the 4 
profiles did not correspond to each other, skin concentration-depth profiles obtained 5 
from MSI analysis showed almost the same tendencies as the calculated ones.   6 
 7 
Fig. 5 8 
 9 
4. Discussion 10 
 The DPK test in the stratum corneum for topically applied drugs by the tape-stripping 11 
method would be helpful for evaluating the bioequivalence of topically applied drugs 12 
(Kalia et al., 2000).  Although LC/MS, LC/MS/MS and accelerator mass spectrometry 13 
are a sensitive technique to detect drug concentration, these are limitations for detecting 14 
its disposition in a tissue correctly.  It is an evidence that Hill equation could be 15 
applied to reveal the relationship between pharmacodynamics or toxicodynamics of 16 
drugs and its tissue concentration.  Therefore, establishment of drug disposition in skin 17 
with an imaging analysis would be very useful for evaluation of safety and effects of 18 
topically applied chemicals.	 In our previous experiment (Kijima et al., 2015), a 19 
non-steady state of drug concentration-skin depth profile could be detected by confocal 20 
laser scanning microscopy after the application of a fluorescent marker, and DPK 21 
parameters could be calculated with Fick’s second law of diffusion. Therefore, in the 22 
 14 
present experiment, the skin concentration-depth profile of topically applied 1 
non-labeled drug was investigated to confirm the possibility of DPK analysis with MSI 2 
analysis.  3 
 A calibration curve to detect the lidocaine concentration in the skin was achieved with 4 
the combination of MSI observation and imaging analysis using Image J software.  In 5 
the present experiment, calibration curve was obtained from immersed skin in different 6 
concentrations of lidocaine solution.  Skin concentration of lidocaine was corrected 7 
with the Kved value that obtained from in vitro skin permeation profile through stripped 8 
skin.  Therefore, when another chemical was selected, the skin concentrations to 9 
calculate skin concentration curve could be corrected with its partition coefficient value.   10 
 Oshizaka et al (2014) reported that skin concentration could be calculated using a skin 11 
resistance model.  Skin permeation resistance in stratum corneum (Rsc), which is equal 12 
to the reciprocal value of the drug permeation coefficient through the stratum corneum 13 
(1/Psc), could be calculated by subtraction of the reciprocal value of the skin permeation 14 
coefficient through full-thickness skin (1/Ptot) to that through stripped skin (1/Pved) 15 
(Scheuplien et al., 1971).  A high Rsc value provides a high drug concentration gradient 16 
across the stratum corneum. Rsc of lidocaine showed about 90% of total skin resistance 17 
and the remaining 10% was Rved in the present study.  Thus, lidocaine concentration 18 
would be dramatically decreased across the stratum corneum in Fig. 6b.  In our 19 
previous study, the lidocaine concentration-distance profile obtained from the skin 20 
permeation profile corresponded well to the observed one (Oshizaka et al., 2014).  21 
Lidocaine concentration-distance profiles obtained from MSI analysis in the stripped 22 
 15 
and full-thickness skin differed from the calculated values.  However, these measured 1 
values obtained from MSI analysis were relatively close to the calculated ones.  Thus, 2 
this method would be applicable for the detection of drug concentration in skin.  When 3 
stripped skin was analyzed with MSI, the observed skin concentrations were lower that 4 
calculated values.  On the other hand, the observed concentrations in the full-thickness 5 
skin was higher than the calculated ones.  These results might be related to lidocaine 6 
diffusion in the skin from high to low concentrations during matrix coverage process 7 
before measurement of lidocaine with MALDI-TOF-MS.  Thus, LC concentration in 8 
stripped skin might be decreased by the diffusion from the inside to the outside of the 9 
skin and the concentration in the full-thickness skin might be increased by the diffusion 10 
from the stratum corneum to the viable epidermis and dermis compared with calculated 11 
values.   12 
 In our previous study (Kijima et al., 2015), drug concentration-depth profiles obtained 13 
from imaging analysis by confocal laser-scanning microscopy at non-steady-state and 14 
steady-state conditions corresponded fairly well with those obtained from the skin 15 
permeation experiments.  The measurement by laser-scanning microscopy was 16 
conducted without a pretreatment procedure.  Thus, improvement of procedure might 17 
be necessary to analyze drug concentration correctly with MSI analysis.  18 
  Bunch et al. (2004), Sjövall et al. (2014), Judd et al. (2013), and D’Alvise (2014) 19 
have investigated the drug distribution in skin using MSI analysis.  In addition, many 20 
reports have been published on the usefulness of MSI analysis as a potential tool for 21 
measurement of the distribution of compounds in tissues (Buck et al., 2015; Hamm et 22 
 16 
al., 2012; Grobe et al., 2012).  Internal standard was not used to conduct the MSI 1 
analysis for detection of lidocaine disposition in the skin in the present study.  To 2 
compensate for variation of the acquired brightness of red spots images, the average 3 
value of brightness was used in the divided skin sections.  Although drug-disposition 4 
profiles in the full thickness skin was achieved by skin-thickness information obtained 5 
from the optical image and the profiles were relatively close to the calculated ones with 6 
two-layered model, this approach would be not suitable for detection of drug 7 
concentration in specific area such as hair follicles, sweat ducts and interfacial layers 8 
between different cells.  Furthermore, skin is histologically composed of three layers 9 
and the line of these layers are not straight, but markedly wavy.  Thus, measurement of 10 
drug skin with divided skin section area might be difficult to measure its concentration 11 
in each layer of the skin.  The use of an internal standard to perform quantitative 12 
analysis should be needed with MSI analysis in the further experiment to analyze more 13 
detail drug distribution in the skin.   14 
   Judd et al (2013) have investigated the detection of drug disposition in the stratum 15 
corneum with ToF-SIMS by the combination of tapa-stripping method. Although 16 
high-sensitive analysis was successfully conducted with this combination approach, 17 
drug concentration in viable epidermis and dermis could not be measured with this 18 
approach. Few studies have reported that a comparison of topically applied drug 19 
concentrations measured by MSI analysis and conventional techniques such as 20 
extraction and tissue homogenization procedures.  Thus, the present work showed the 21 
usefulness of MSI analysis technique to evaluate drug disposition and concentration in 22 
 17 
skin after its topical application.  This approach would be complementary method to 1 
evaluation of skin permeation of drugs with conventional diffusion cells.     2 
 3 
5. Conclusion 4 
    Investigation of the dermatopharmacokinetics (DPK) should be performed to 5 
develop topical formulations and drug formulas.  In the present study, only the 6 
lidocaine distribution in skin was evaluated.  To clarify the usefulness of this approach, 7 
the skin distribution of compounds with a wide range of physicochemical properties 8 
should be investigated.  Although further experiments involving DPK analysis with the 9 
obtained data are required, this result suggests that the drug concentration profile in 10 
viable epidermis and dermis could be obtained, and evaluations of the safety and effect 11 
of chemicals as well as evaluation of their disposition in the skin might be conducted by 12 
observation using MSI.  13 
 14 
  15 
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Figure captions 1 
Figure 1  Skin permeation of lidocaine through full-thickness skin () and stripped 2 
skin (). The mean ± S.E. (n=4). 3 
 4 
Figure 2  Typical MALDI mass spectrum, which was collected from m/z= 200 to 900, 5 
in skin sections without a) and with b) topical application of lidocaine at a concentration 6 
of 2500 µg/ml.    7 
 8 
Figure 3  Example of an IMS observation image for lidocaine intensity in a 9 
full-thickness pig ear skin section after the permeation experiment. a) Optical image of 10 
a vertical skin section. b) MSI image observation of distribution of lidocaine in skin 11 
after its topical application. The skin section was decided by the positional information 12 
of the obtained image. Abbreviation: SC, stratum corneum. 13 
 14 
Figure 4  Calibration curve between applied lidocaine concentration [(i) 0 µg/mL, (ii) 15 
500 µg/mL, (iii) 1500 µg/mL, and (iv) 2500 µg/mL] and its brightness.  a) Optical 16 
image of skin (the MSI observed area is enclosed with black lines).  b) MSI 17 
observation image in skin.  c) Calibration curve obtained from applied lidocaine 18 
concentration and its intensity.  Each pixel was 10 µm in width.  Each point 19 
represents the mean ± S.E. (n=5). 20 
 21 
Figure 5  The optical and MSI observations of lidocaine after its topical application to 22 
 24 
stripped (a and c) and full-thickness skins (b and d).  a) and b) are optical images of a 1 
skin section, whereas c) and d) are MSI images.  Scale bar shows 100 µm.  2 
 3 
Figure 6  Lidocaine concentration-depth profile in a) stripped and b) full-thickness 4 
skin and c) enlargement of b) in terms of the scale of the y-axis.  The value of abscissa 5 
(x/L) calculated from the ratio, which obtained from the positional information.  L is 6 
set to be 1300 µm from the surface of the skin. 7 
Symbols: , lidocaine concentration calculated from skin permeation parameters; , 8 
concentration observed by MSI image analysis.   9 
  10 
 25 
Table 1  Permeation parameters obtained from the skin permeation profile of LC 
Drug Skin permeation parameters 
LC 
Ptot (cm/s) 7.97 Í10-7 ± 8.8Í 10-8 
Pved (cm/s) 6.37 Í 10-6 ± 4.1 Í 10-7 
Dsc (cm2/h) 8.5 Í 10-7 
Dved (cm2/h) 2.2 Í 10-3 
Ksc 9.5  
Kved 1.7  
Ptot : skin permeation coefficient through the full-thickness skin 
Pved: skin permeation coefficient through the stripped skin 
Dsc: diffusion coefficient of drug in the stratum corneum 
Dved: diffusion coefficient of drug in the viable epidermis/dermis 
Ksc: diffusion coefficient of drug in the stratum corneum 
Kved: diffusion coefficient of drug in the stratum corneum 
Thicknesses of the stratum corneum and viable epidermis/dermis were 
set to be 15 µm and 1485 µm, respectively. 
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